RIPK3-IN-1 是 II 型RIPK3DFG-out 位点抑制剂，IC50为 9.1 nM。RIPK3-IN-1 抑制 RIPK1 和 RIPK2，IC50为 5.5 和 >10 μM。RIPK3-IN-1 还是 c-Met 激酶抑制剂，IC50为 1.1 μM。

RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC 50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC 50 s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC 50 of 1.1 μM [1].

RIPK3-IN-1 (Compound 18) also inhibits ABL, BRAF/V599E, MAP4K3, and SRC with IC 50 s of 0.37, 0.15, 0.012, and 0.075 μM, respectively [1]. Necroptosis is a programmed form of cell death and has been associated with a variety of diseases, including ischemia reperfusion injury, neurodegenerative disorders, pancreatic cancer, and autoimmune diseases such as inflammatory bowel disease (IBD). Upon stimulation of death receptors (such as the family of TNF receptors), signaling can initiate a necroptotic cell death process. This involves formation of a necrosome, which includes receptor interacting protein kinases 1 and 3 (RIPK1, RIPK3) in a cytosolic complex [1].

2361139-70-8

C29H25FN4O4

512.53

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years